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Introduction: Parkinson’s disease, whose prevalence in Colombia is 4.7 per 1,000 inhabitants, is a 
public health problem and a therapeutic challenge for health professionals.
Objective: To determine the prescribing patterns of antiparkinson drugs and the variables associated 
with its use in a population from Colombia.
Materials and methods: We conducted a descriptive cross-sectional study. We selected patients who 
had been given antiparkinson drugs uninterruptedly between January 1st and March 31st, 2015 from a 
systematized database of approximately 3.5 million people affiliated to the Colombian health system. 
We included sociodemographic, pharmacologic and comedication variables. For the multivariate 
analysis, we used the IBM SPSS™-22 software.
Results: A total of 2,898 patients was included; the mean age was 65.1years, and 50.7% were men; 
69.4% (n=2010) of people received monotherapy and 30.6% combination therapy with two to five 
antiparkinson drugs. The most frequently prescribed drugs were: levodopa 45.5% (n=1,318 patients), 
biperiden 23.1% (670), amantadine 18.3% (531) and pramipexole 16.3% (471). The most commonly 
used association was levodopa/carbidopa + entacapone (n=311; 10.7%). Multivariate analysis showed 
that being male (OR=1.56; 95%CI: 1.321-1.837), over 60 years (OR=1.41; 95%CI 1.112-1.782) 
and receiving treatment in the city of Barranquilla (OR=2.23; 95%CI 1.675-2.975) were statistically 
associated with a greater risk of using combination therapy; 68.2% (n=1,977) patients were given 
concomitant treatment with other drugs.
Conclusions: Prescribing habits of drugs with high therapeutic value predominated, mainly in 
antiparkinson drugs monotherapy. Most were employed in the usual recommended doses. It is 
necessary to explore the clinical effectiveness of the medications studied and differentiate between 
disease and parkinsonian syndromes subtypes.
Key words: Parkinson disease; antiparkinson agents; pharmacoepidemiology; drug prescriptions; 
drug utilization; Colombia.
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Patrones de prescripción de fármacos antiparkinsonianos en un grupo de pacientes de 
Colombia, 2015 
Introducción. La enfermedad de Parkinson, cuya prevalencia en Colombia es de 4,7 por 1.000 
habitantes, constituye un problema de salud pública y un reto terapéutico para los profesionales de 
la salud.
Objetivo. Determinar los patrones de prescripción de fármacos antiparkinsonianos y las variables 
asociadas con su utilización en una población colombiana.
Materiales y métodos. Se hizo un estudio descriptivo de corte transversal. A partir de una base de 
datos de 3,5 millones de afiliados al sistema de salud, se seleccionaron pacientes con prescripción de 
medicamentos antiparkinsonianos de manera ininterrumpida entre el 1º de enero y el 31 de marzo de 
2015. Se incluyeron variables sociodemográficas, farmacológicas y de medicación concomitante. El 
análisis multivariado se hizo con el programa IBM SPSS™-22.
Resultados. Se hallaron 2.898 pacientes, con una edad media de 65,1 años, de los cuales el 50,7 %                             
correspondía a hombres. El 69,4 % (n=2.010) de las personas recibía monoterapia y el 30,6 %, 
tratamiento combinado con dos a cinco medicamentos antiparkinsonianos. Los más prescritos eran la 
levodopa (45,5 %; n=1.318 pacientes), el biperideno (23,1 %; n=670), la amantadina (18,3 %; n=531) y 
el pramipexol (16,3 %; n=471). La asociación más utilizada fue la de levodopa-carbidopa y entacapone 
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(n=311; 10,7 %). En el análisis multivariado se encontró que ser hombre (odds ratio, OR=1,56; IC95% 
1,321-1,837), ser mayor de 60 años (OR=1,41; IC95% 1,112-1,782) y recibir tratamiento en Barranquilla 
(OR=2,23; IC95% 1,675-2,975), se asociaban con una mayor probabilidad de emplear el tratamiento 
combinado. Al 68,2 % (n=1.977) de los pacientes se les había prescrito tratamiento concomitante con 
otros medicamentos. 
Conclusión. Predominaron los hábitos de prescripción de medicamentos con gran valor terapéutico, 
principalmente en la monoterapia, la mayoría en las dosis usuales recomendadas. Es necesario 
explorar la efectividad clínica de las prescripciones estudiadas, y diferenciar entre la enfermedad y los 
subtipos de síndromes parkinsonianos.
Palabras clave: enfermedad de Parkinson; antiparkinsonianos; farmacoepidemiología; prescripciones 
de medicamentos; utilización de medicamentos; Colombia.
doi: https://doi.org/10.7705/biomedica.v38i4.3781
Parkinson’s disease is the second most common 
movement disorder in the world and the second 
most frequent neurodegenerative disease. It is 
characterized by nigrostriatal neuronal loss and 
the presence of alpha-synuclein inclusion bodies 
called Lewy bodies, with a subsequent dopamine 
deficiency (1).
The estimated global incidence is about 4.5-19 
cases per 100,000 inhabitants a year and preva-
lence varies between 71 and 258 cases per 100,000 
people as reported by the World Health Organiza-
tion (WHO). In the case of Europe, the prevalence 
is 100-200 cases per 100,000 people (1,2). There 
is an increased prevalence with advanced age, 
and between 1% and 2% of the population over 65 
years suffer from the disease (3-5).
The costs of the pathology in the United Kingdom 
are estimated to be £3.3 billion and in the United 
States, the cost per patient per year is about USD$ 
10,000, which is equivalent to a total cost of the 
disease of USD$ 23 billion per year (6).
In Colombia, the reported prevalence of Parkinson’s 
disease in those over 50 years of age varies from 
1.76 (95%CI 1.66-1.86) up to 4.7 (95%CI 2.20-8.90) 
per 1,000 inhabitants, predominantly male (7-9). 
Through the capture-recapture method, it has been 
established that of 551 individuals, 80.4% suffer 
idiopathic Parkinson’s disease and the remaining 
19.6% suffer from Parkinsonian syndrome, includ-
ing that secondary to drugs. It is estimated that 
180,000 persons have the disease in the country, 
making it a public health problem (10).
Today, the options for providing drug treatment 
have increased extensively, with around a dozen 
of active principles grouped into six different phar-
macological groups, which are used not only in 
Parkinson’s disease but in other Parkinsonian 
syndromes and in the drug-induced type, among 
other indications.
The Colombian health system (Sistema General de 
Seguridad Social en Salud, SGSSS) contemplates 
a list of drugs within the benefit plan for its affiliates 
that includes several drugs for the above-mentioned 
morbidities. In this context and given that no studies 
on the use of these drugs in Colombia was found, 
the main objective of this study was to determine 
the prescribing patterns of antiparkinson drugs 
and the variables associated with their use in the 
country. This may also help to gain data that could 
lead to the improvement and update of programs 
aimed at achieving a proper use of and better 
patient-targeted treatment.
Materials and methods
This was a cross-sectional study on the prescribing 
habits of antiparkinson drugs in a population of 
approximately 3.5 million people affiliated to the 
contributory scheme of the SGSSS in five health 
insurance companies (Empresas Prestadoras de 
Servicios, EPS), corresponding to about 15.9% 
of the active population affiliated to this regime in 
the country and to 7.2% of the Colombian popula-
tion. We analyzed the prescription data of patients 
treated between 1st January and 31st March of 2015 
in 60 Colombian cities.
Data included individuals of all ages and of either 
sex who were receiving antiparkinson drugs and 
whose treatment was maintained uninterrupted for 
at least 3 months. This requirement was meant to 
ensure that patients complied consistently with the 
treatment, reflecting tolerability and adherence to 
the medication, while those people who missed 
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prescriptions during the observation period were 
excluded, as it was considered that these indivi-
duals would introduce a bias into a study that aimed 
to describe patterns of medications continuously.
From the information on the consumption of drugs, 
systematically obtained by the dispensing com-
pany Audifarma, S.A., a database was designed 
that allowed the collection of the following groups 
of variables: 
1. Sociodemographic: gender, age (adult: 18-64 
years old, young-old: 65 to 74 years, old: 75 to 84 
years, and oldest-old: 85 or more years) and city; 
2. antiparkinson drug: drug name, dosage and 
quantity delivered. 
The defined daily dose (DDD) was used as the unit 
of measure of the usage of the following drugs, as 
recommended by the WHO, and expressed as 
defined daily dose (DHD) per 1,000 inhabitants 
per day: 
a) precursor of dopamine (levodopa-carbidopa, 
levodopa-benserazide);
b) anticholinergic drug (biperiden); 
c) dopamine receptor agonists (cabergoline, 
rotigotine, pramipexole, etc.); 
d) inhibitors of catechol-o-methyl transferase 
[COMT] (entacapone); 
e) N-methyl-D-aspartate [NMDA] receptor antago-
nist (amantadine), and
f) monoamine oxidase-B inhibitors (selegiline, 
rasagiline).
The unitary and total costs, and the cost per 
1,000 inhabitants/day (CHD= [cost/365 x number 
of inhabitants]x 1,000) were used to estimate 
the economic impact of the dispensation of anti-
parkinson drugs using the average price of the 
most commonly used drug presentation and the 
reference price of the distribution company for 
different EPS (reference value according to the 
Bank of the Republic of Colombia: USD$ 1 = COP$ 
2,576 Colombian pesos (on 31st March, 2015).
Comedication was accepted as a substitute indi-
cator of chronic disease, considering the following 
circumstances: 
a) antidiabetics and insulins/diabetes mellitus; 
b) antiulcer medication/peptic ulcer disease; 
c) psychostimulants/apathy, anhedonia and drow-
siness; 
d) antidepressants/depressive disorder; 
e) anxiolytics and hypnotics/anxiety or sleep 
disorders; 
f) lipid-lowering medication/dyslipidemia; 
g) thyroid hormone/hypothyroidism; 
h) nitrovasodilators/ischemic heart disease; 
i) diuretics and antihypertensives/hypertension; 
j) mood stabilizers/bipolar affective disorder; 
k) antipsychotics/psychosis-schizophrenia; 
l) antidementia/dementia and Alzheimer’s disease; 
m) antithyroid medication/hyperthyroidism; 
n) anticonvulsants/epilepsy; 
o) bronchodilators/asthma or chronic obstructive 
pulmonary disease; 
p) laxative/constipation; 
q) antiemetic/nausea; 
r) analgesics/pain. 
In such cases, the convenience of the association 
with the antiparkinson drug was analyzed based 
on the pharmacological effects they may have on 
comorbidity.
The protocol received the approval of the bio-
ethics committee of the Universidad Tecnológica 
de Pereira and was classified as “research 
without risk”, safeguarding the identity of the 
patients according to the recommendations of the 
Declaration of Helsinki. 
The statistical package SPSS™ Statistics 22.0 
(IBM, USA) for Windows was used for data 
analysis. Descriptive statistics were used: means, 
standard deviation, minimum and maximum values 
for continuous variables and percentages for 
categorical variables. T-test or ANOVA was used 
for quantitative variables comparison and c2 for 
categorical. A logistic regression model was per-
formed using as a dependent variable the use of 
antiparkinson drugs alone or in combination (yes/
no), and also the need for comedications (yes/no), 
and as covariates those significantly associated 
with them in the bivariate analyses. The statistical 
significance level was determined as p<0.05.
Results
From 2,898 patients affiliated to SGSSS on treat-
ment with antiparkinson drugs for a period of not 
less than 3 months, the distribution by gender 
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showed that 1,468 (50.7%) were men and 1,430 
(49.3%) women, with a mean age of 65.1 ± 16.0 
years (rank: 16.5-103.2 years); the distribution by 
age groups identified 972 adults (33.5% of the 
patients), 519 (17.9%) young-old, 529 (18.3%) old 
and 174 (6.9%) oldest-old. It stood out that 1,570 
patients (54.2%) were over 60 years of age (figure 1).
Table 1 summarizes the prescribing patterns of anti-
parkinson drugs most frequently used in Colombia. 
Considered by pharmacological groups, 45.5% 
of patients were using levodopa, while 31.6% 
received a dopamine agonist. Levodopa-carbidopa 
and amantadine were being used at usual doses, 
pramipexole and selegiline were being used above 
the DDD, while cabergoline and biperiden were 
below. In this study, no patient was prescribed with 
pergolide, tolcapone or trihexyphenidyl.
Monotherapy versus combination therapy
Of the total study patients, 2,010 (69.4%) were 
prescribed with one, while 888 (30.6%) received 
a combination of two or more antiparkinsonian 
agents. There were 687 (23.7% of the total) patients 
receiving two drugs, 155 (5.3%) receiving three, 
44 (1.5%) receiving four, and even two (0.1%) 
patients receiving five of these drugs. Figure 2 
shows the relationship between monotherapy 
and combination therapy for some of the drugs 
that were evaluated, and that monotherapy was 
more usual than combination therapy. Statistically 
significant differences were found between those 
receiving monotherapy according to sex (women: 
74.3% vs. men: 64.5%; p<0.001).
Among the 888 patients who were prescribed 
with antiparkinson drugs combinations, the most 
frequently used were: levodopa/carbidopa + 
entacapone (n=311; 10.7%), levodopa/carbidopa + 
amantadine (n=152; 5.2%), levodopa/carbidopa + 
pramipexole (n=52; 1.8%), and levodopa/carbidopa 
+ biperiden (n=35; 1.2%).The most common 
combinations of three of these drugs were: 
levodopa/carbidopa + entacapone + pramipexole 
(n=38; 1.3%), levodopa/carbidopa + entacapone + 
amantadine (n=25; 0.9%) followed by levodopa/car-
bidopa + amantadine + pramipexole (n=16; 0.5%).
Multivariate analysis of the relationship between 
the use of antiparkinson combination therapy and 
other variables showed that being male, being 
over 60 years of age, being treated in the city of 
Barranquilla, and being affiliated with the EPS 1 
were statistically associated with a greater likelihood 
of receiving combined therapy, while being an adult 
between 18 and 64 years was associated with a 
lower probability of being treated with more than 
one drug from the group (table 2).
Comedication
Parkinson’s disease and Parkinsonian syndrome 
are often accompanied by comorbidities that need 
additional treatment. Among the subjects included, 
1,977 patients (68.2%) concomitantly received 
one or more of the following groups of drugs 
that reflect comorbidity and could interact with 
some antiparkinsonian agents: antihypertensives 
(n=956; 33.0% of the patients); lipid-lowering 
drugs (n=756; 26.1%); analgesics (n=685; 23.6%); 
antiulcer medication (n=671; 23.2%); diuretics 
(n=450; 15.5%); classical antipsychotics (n=387; 
13.4%); atypical antipsychotics (n=381; 13.1%); 
levothyroxine (n=355; 12.2%); oral hypoglycemic 
agents and insulins (n=274; 9.4%, and from these, 
28.5% were using insulin); atypical antidepres-
sants (n=256; 8.8%); benzodiazepines and z-drugs 
(n=235; 8.1%); lamotrigine and valproic acid 
(n=190; 6.1%); laxatives (n=177; 6.1%); inhaled 
bronchodilators (n=141; 4.9%); gabapentin or 
pregabalin (n=142; 4.9%); tricyclic antidepressants 
(n=25; 4.3%); antidemential medications (n=116; 
4.0%); metoclopramide (n=42; 1.4%); oxybutynin 
or tolterodine (n=22; 0.8%). None of the patients 
received lithium.
No statistically significant differences were found 
between receiving comedication and sex (male: 
68.7% vs. female: 67.8%). A statistically significant 
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Figure 1. Distribution of 2,898 patients treated with antiparkinson 
medication by age and sex, Colombia, 2015
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Figure 2. Frequency of antiparkinson medication prescription in combination therapy or monotherapy, Colombia, 2015. 
Table 1. Prescription patterns of antiparkinson drugs used in 2,898 patients in Colombia, 2015
Medication Prescriptions
/users
Prescribed dose 
(mg/day)
Sex 
ratio 
M:F
Mean age
(SD)
Range
# patients % Mean Mode
Levodopa total 1318 45.5 563.7 500 1.2:1 72.2 (11.5) 30-101
Levodopa/carbidopa tablet 869 30.0 600.0 500 1.2:1 72.5 (11.3) 30-101
100 + 25 mg 94  3.2 350.9 400 0.7:1 72.3 (11.5) 41-  99
250 + 25mg 776 26.8 629.4 500 1.3:1 72.5 (11.3) 30-101
Levodopa/benserazide tablet 
200 + 50 mg 
16 0.6 525.0 800 0.5:1 75.4 (10.0) 57-  91
Entacapone/levodopa/carbidopa* 
coatedtablet
445 15.4 712.5 / 479.1 600 / 300 1.5:1 71.3 (12.1) 30-  91
200 + 100 + 25 mg 205 7.1 609.8 / 304.9 600 / 300 1.4:1 72.4 (11.2) 30-  89
200 + 150 + 37.5 mg 101 3.5 806.6 / 604.9 800 / 600 1.4:1 68.6 (13.4) 31-  90
200 + 200 + 50 mg 95 3.3 869.5 / 869.5 800 / 800 2.7:1 69.5 (13.3) 36-  91
200 + 50 + 12.5 mg 44 1.5 636.4 / 159.1 600 / 150 0.8:1 74.6   (9.3) 50-  90
Biperiden tablet 2 mg 670 23.1 3.7     4 1.4:1 57.4 (16.8) 16-101
Amantadine tablet 100 mg 531 18.3 204.7 200 0.9:1 69.7 (11.9) 27-  96
Pramipexole sustained release tablet 471 16.3 2.7     3 1.0:1 68.0 (10.9) 35-  95
0.375 mg 31 1.1 0.4            0.375 0.6:1 67.5 (11.7) 46-  82
0.75 mg 60 2.1 0.9          0.75 0.8:1 70.1 (10.0) 43-  88
1.5 mg 116 4.0 1.7        1.5 0.8:1 69.3 (11.9) 35-  91
3.0 mg 156 5.4 3.2     3 1.3:1   67.5   (1.06) 38-  95
4.5 mg 111 3.8 4.6        4.5 1.5:1 66.2 (10.4) 40-  90
Cabergoline tablet 0.5 mg 205 7.1 0.1          0.07 0.2:1 41.8 (11.8) 17-  81
Rotigotine transdermal patch 142 4.9 17.8      16.8 1.1:1 68.5 (10.9) 36-  87
18 mg 92 3.2 20.5      16.8 1.0:1 67.1 (11.8) 36-  85
13.5 mg 27 0.9 15.2      12.6 0.9:1 70.6   (8.1) 51-  83
9 mg 26 0.9 9.2        8.4 2.3:1 71.0   (9.8) 51-  87
Rasagiline tablet 134 4.6 1.0     1 1.2:1 66.5 (11.9) 35-  95
0.5 mg 23 0.8 0.6        0.5 0.9:1 68.5 (10.5) 50-  83
1 mg 111 3.8 1.0     1 1.2:1 66.1 (12.2) 35-  95
Bromocriptine tablet 2.5 mg 100 3.5 4.1        2.5 0.4:1 57.1 (18.1) 17-103
Selegiline tablet 5 mg 8 0.3 9.2   10 1.7:1 75.1   (8.5) 65-  85
* Calculations based on entacapone/levodopa; M:F= male:female; SD: Standard deviation
results, and in
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association was found between receiving biperiden 
and atypical antipsychotics (OR=8.87; 95%CI 6.97-
11.29) and classical antipsychotics (OR=184.17; 
95%CI 107.99-336.10).
The multivariate analysis of the relationship 
between the use of comedication and other vari-
ables showed that using biperiden, levodopa/
benserazide, rasagiline, and being treated in 
the cities of Pereira or Palmira were statistically 
associated with more probability of receiving other 
drug groups. While the variables being male, the 
use of amantadine, being treated in the city of 
Bogotá and belonging to EPS 1, 2, 3, and 5 were 
associated with a lower likelihood of receiving any 
comedication (table 3).
Comparison between cities
We compared the demographic variables and some 
prescribing indicators among the 60 Colombian 
cities included in this study; however, because of 
the low number of patients in some of them, table 4 
only shows the seven largest, where 74.7% of the 
people evaluated resided. It can be seen that the 
differences were significant for the frequency of 
the use of monotherapy and for the comedication. 
Table 2. Multivariate analysis of variables associated with combination treatment in patients on antiparkinson medication, 
Colombia, 2015
Variables B SE Wald DF Sig. OR 95% CI
Lowest Highest
Male sex 0.443 0.08 27.75 1.00 <0.001 1.56 1.321 1.837
Adult -0.704 0.11 38.02 1.00 <0.001 0.49 0.396 0.619
Young-old -0.014 0.14 0.01 1.00 0.922 0.99 0.752 1.295
Middle-old 0.114 0.14 0.69 1.00 0.406 1.12 0.857 1.465
>60 years 0.342 0.12 8.06 1.00 0.005 1.41 1.112 1.782
City of Barranquilla 0.803 0.15 30.03 1.00 <0.001 2.23 1.675 2.975
City of Palmira 0.220 0.24 0.86 1.00 0.354 1.25 0.782 1.986
EPS 1 0.513 0.12 18.66 1.00 <0.001 1.67 1.324 2.109
EPS 3 -0.068 0.14 0.24 1.00 0.628 0.93 0.711 1.229
EPS 4 0.232 0.15 2.47 1.00 0.116 1.26 0.944 1.683
Constant -1.402 0.13 108.87 1.00 0.000 0.25   
B: Regression coefficient; SE: Standard error; DF: Degrees of freedom; Sig: Significance; OR: odds ratio; 95% CI: Confidence interval of 95 %. EPS: 
Health insurance company
Table 3. Multivariate analysis of variables associated with antiparkinson treatment with comedications, Colombia, 2015
Variables B SE Wald DF Sig. OR 95% CI
Lowest Highest
Male sex -0.34 0.10 12.25 1.00 <0.001 0.71 0.589 0.861
Amantadine use -0.28 0.12 5.39 1.00 0.020 0.76 0.598 0.957
Biperiden use 3.91 0.25 249.32 1.00 <0.001 49.77 30.644 80.843
Entacapone/levodopa use 1.77 0.15 147.84 1.00 <0.001 5.86 4.409 7.799
Levodopa/benserazide use 0.66 0.14 23.44 1.00 <0.001 1.93 1.481 2.527
Levodopa/carbidopa use -0.08 0.55 0.02 1.00 0.887 0.93 0.317 2.698
Rasagiline use 1.32 0.11 133.34 1.00 <0.001 3.73 2.985 4.667
MAOI use 0.02 0.80 0.00 1.00 0.977 1.02 0.215 4.869
Young-old -0.32 0.77 0.17 1.00 0.678 0.73 0.159 3.309
Bogotá -0.94 0.18 26.37 1.00 <0.001 0.39 0.271 0.558
Pereira 0.60 0.21 8.45 1.00 0.004 1.82 1.216 2.730
Palmira 1.03 0.36 8.16 1.00 0.004 2.79 1.380 5.638
EPS1 -1.37 0.22 40.47 1.00 <0.001 0.25 0.167 0.388
EPS2 -1.43 0.23 39.59 1.00 <0.001 0.24 0.154 0.374
EPS3 -0.90 0.23 14.56 1.00 <0.001 0.41 0.258 0.647
EPS5 -1.17 0.21 31.87 1.00 <0.001 0.31 0.206 0.465
Constant 1.01 0.22 20.78 1.00 0.000 2.75   
B: Regression coefficient; S.E.: Standard error; DF: Degrees of freedom; Sig: Significance; OR: Odds ratio; 95% CI: Confidence interval of 95%; MAOI: 
Monoamineoxidase inhibitors; EPS: Health insurance company
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The consumption of antiparkinson drugs was also 
presented as a percentage of DDD so that they 
could be useful in later comparisons.
Economic analysis
It is estimated that on average 0.231 DDD per 
1,000 inhabitants/day of levodopa/carbidopa are 
consumed, 0.069 DDD per 1,000 inhabitants/day 
of biperiden and 0.154 DDD of amantadine per 
1,000 inhabitants/day. The total cost of dispensing 
levodopa/carbidopa for the affiliated population 
per year was COP$ 167,398,836 (USD$ 64,984). 
The cost of a prescribed daily dose for the 250/25 
mg tablet was COP$ 331.5 (USD$ 0.13), and the 
CHD was COP$ 73.4 (USD$ 0.03), while the daily 
cost for the 100/25 mg tablet was COP$ 2,185 
(USD$ 0.85).
The total cost of the dispensation of biperiden 
to the affiliated population for a year was COP$ 
49,959,408 (USD$ 19,392). The cost of a pre-
scribed daily dose for a 2 mg tablet was COP$ 
203.9 (USD$ 0.08), and the CHD was COP$ 39.3 
(USD$ 0.02). The total cost of the dispensation 
of amantadine was COP$ 172,550,624 (USD$ 
66,984). The cost of a prescribed daily dose for 
100 mg tablets was COP$ 903.8 (USD$ 0.35), 
and the CHD was COP$ 135.9 (USD$ 0.05).
Discussion
This study allowed us to determine the prescribing 
patterns of the antiparkinson drugs used most 
frequently with patients affiliated to the SGSSS of 
Colombia; these findings can be used by health 
managers to make decisions aimed at improving 
the health care of patients with Parkinson’s disease 
and other movement disorders.
The distribution by sex and age of Parkinson’s 
disease worldwide is diverse depending on the 
study design, geographic location, and ethnicity 
(1). Studies in Japan and Italy reported that over 
Table 4. Comparison of some demographic variables and prescribing indicators of antiparkinson medications among Colombian 
cities, 2015 
Variable Cali Bogotá Barranquilla Pereira Palmira Cartagena Manizales Colombia
n=721 n=702 n=311 n=182 n=85 n=83 n=80 n = 2898
Mean age (SD) 64.6 (16.2) 62.9 (16.7) 65.5 (14.3) 69.7 (14.0) 66.9 (16.1) 58.7 (19.4) 66.3 (16.5) 65.1 (16.0)
Male (%) 54.6 44.3 52.7 45.6 56.5 57.8 48.8 50.7
Monotherapy (%) 72.1 70.9 59.2 72.0 58.8 78.3 73.8 69.4
Comedication (%) 70.6 56.8 66.2 78.6 87.1 74.7 60.0 68.2
Prescription (%)        
Levodopa total 39.8 50.7 43.1 42.9 55.3 30.1 57.5 45.5
Levodopa/carbidopa 26.1 30.6 28.6 24.2 36.5 24.1 45.0 30.0
Biperiden 35.6 6.6 19.3 13.2 35.3 44.6 7.5 23.1
Amantadine 16.1 11.1 36.3 30.2 11.8 10.8 11.3 18.3
Pramipexole 10.8 20.7 16.4 14.3 12.9 12.0 32.5 16.3
Entacapone/levodopa/
carbidopa
13.2 20.5 15.1 18.7 20.0 6.0 12.5 15.4
Cabergoline 5.5 10.4 6.8 6.6 1.2 10.8 7.5 7.1
Rotigotine 3.5 6.1 10.9 2.2 2.4 8.4 5.0 4.9
Rasagiline 4.2 3.3 15.4 3.8 3.5 3.6 2.5 4.6
Bromocriptine 2.9 5.3 0.3 2.7 3.5 1.2 8.8 2.0
Levodopa/benserazide 1.1 0.0 0.0 0.0 1.2 0.0 0.0 3.5
Selegiline 0.3 0.1 0.6 0.5 0.0 0.0 0.0 0.3
Mean daily dose to DDD ratio
Levodopa total 0.8 1.1 0.9 0.9 0.8 1.0 0.9 0.9
Levodopa/carbidopa 0.9 1.1 1.0 0.9 1.0 1.0 0.9 1.0
Biperiden 0.4 0.4 0.4 0.3 0.4 0.4 0.4 0.4
Amantadine 1.1 1.0 1.1 0.8 0.9 1.3 1.0 1.0
Pramipexole 1.0 1.1 0.8 1.2 0.8 1.3 1.0 1.1
Entacapone/levodopa/
carbidopa
0.7 0.8 0.7 0.7 0.7 0.7 0.8 0.7
Cabergoline 0.03 0.03 0.06 0.03 0.03 0.04 0.03 0.03
Rasagiline 1.0 1.0 0.9 1.0 1.0 1.1 1.0 1.0
Bromocriptine 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
Levodopa/benserazide 0.8 - - - 0.7 - - 0.9
Selegiline 2.0 2.0 1.8 2.0 - - - 1.8
DDD: Defined daily dose
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55.0% of patients were women (11,12), while in 
Sweden 53.9% were men (13). The fact that no sex 
differences were found after 60 years of age differs 
from the literature where after this age there is a 
predominance of males (1).
Levodopa/carbidopa is the most commonly used 
drug in different studies, and in this case, since it is 
part of the closed list of drugs that make up the plan 
of benefits from the SGSSS, its use as gold standard 
treatment is encouraged (11-13). Otherwise, other 
medications such as the dopamine agonists, which 
are not included in this list, had a lower prescription 
(11,14); but it should be clarified that it is possible to 
prescribe drugs outside the list, requested through 
the evaluation of a scientific technical committee 
or with legal tools for the protection of rights (14). 
The order of frequency could represent the current 
recommendations for levodopa use, which is 
preferred in people over 60 years of age (the most 
prevalent in this study population), and leaving the 
use of dopamine agonists for younger patients 
with the disease (4,15). It is noteworthy that most 
antiparkinsonian medications are being used at 
the recommended DDD.
Recent studies have shown similar data on mono-
therapy (63.0-71.0%) (16), but there are also 
reports of increased use of combination therapy 
(50.0%) (12). In the present work, the most frequent 
combination corresponds to levodopa/carbidopa 
plus entacapone, unlike other studies where the 
levodopa/carbidopa plus dopamine agonist asso-
ciation was the most prescribed (12,17).
The analysis of comorbidities showed that they 
mostly correspond to common diseases in elderly 
patients, such as hypertension and dyslipidemia, 
which is consistent with the mean age of the 
study patients, although the proportion of patients 
with diabetes mellitus in this study is lower than 
expected for this age group in general; however, 
there have been prevalence reports as low as 1.6% 
in patients with Parkinson’s disease (12).
It is important to note that a large proportion of 
patients received analgesics and antiulcer drugs, 
which is not consistent with results from other 
studies where comedication with these groups of 
drugs does not reach 10%. A high consumption 
of antipsychotics was observed (26.5% of the 
patients), associated with the use of biperiden, 
an expected outcome as this is a drug commonly 
used for the management of induced Parkinson, 
especially by neuroleptics (3,18). In the group of 
antidepressants, the frequency of use was less 
than 10%, contrary to those reported in a study with 
patients diagnosed with Parkinson’s disease where 
depression was identified in about 35% of patients, 
which may indicate underdiagnosis in this group of 
patients (19). 
Another important aspect of comedication was 
the presence of drugs used for the management 
of non-motor symptoms of Parkinson’s that 
relate especially to autonomic disorders, such 
as the use of laxatives in constipation, the use 
of oxybutynin and botulinum toxin for alterations 
in frequency and urinary urgency, or inhibitors 
of 5-phosphodiesterase in erectile dysfunction 
(0.1% in this study versus 68.0% in patients with 
Parkinson) (20,21). This may be an indicator that 
non-motor manifestations are not identified in the 
medical controls of these patients, and worse, they 
are not being treated, which can affect the patient’s 
quality of life.
The estimated costs of treatment with the major 
antiparkinson drugs identified in the study were 
lower than those reported for other populations 
(6,22), possibly because generic drugs are used in 
most cases and some of these prices are regulated 
by the health authorities. 
The differences regarding prescribing patterns 
between different Colombian cities in the study, 
including the frequencies of use of some anti-
parkinson medications (table 4), are not surprising, 
since variability in health care, particularly in pre-
scribing habits, is a constant finding in pharmaco-
epidemiologic studies (23).
This research has certain limitations regarding the 
interpretation of some results because the informa-
tion was obtained from databases and not directly 
from the patient or the prescriber, and no medical 
records were consulted, which will be addressed 
with further drug-utilization studies in the second 
phase of this research line. It is necessary to collect 
information about the classification as Parkinson’s 
disease or Parkinsonian syndrome subtype, the 
incidence of adverse events, adherence to pre-
scribed treatment, the degree of control of symptoms 
and the impact on the quality of life. Since these 
variables were not assessed, it is unknown whether 
the prescription was either needed or appropriate. 
It is noteworthy that the data come from a captive 
population receiving drugs on a specific list, so the 
findings apply to populations with similar charac-
teristics of insurance and health care.
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From the prescribing patterns found in this 
study, it can be concluded that, in general, the 
drug-prescribing habits of medications with high 
therapeutic value included in the list of essential 
drugs in the country, mainly in monotherapy and 
at recommended doses, predominate. A significant 
number of patients receiving classical and atypical 
antipsychotics was found; this was associated 
with drug-induced Parkinsonism, which leads to 
the use of biperiden in particular. Hypertension, 
dyslipidemia and pain management were the most 
common comorbid conditions. 
It is recommended to conduct new studies to 
describe the effectiveness of antiparkinson treat-
ment in this group of patients by assessing the 
relevance of the dosing and the comedication they 
receive and providing useful tools to reduce the risk 
of interactions. Meanwhile, programs of continuing 
medical education including the results of this study 
can be implemented aimed at treating physicians 
of this group of patients as a strategy to improve 
the prescription of antiparkinson drugs, as has 
been described before for other pathologies (24).
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